Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jeevan Scientific TechnologyBOM:538837 +1.17%65 Pretax Margin % is 12.05% as of Mar. 2026, which is 365% above its 10-year median of 2.59. GuruFocus rates BOM:538837 with a GF Score™ of 65/100 and a GF Value™ of ₹61.75 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 942 Biotechnology companies, Jeevan Scientific Technology ranks better than 74.2% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Jeevan Scientific Technology Pretax Margin % Related Terms
Jeevan Scientific Technology Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:538837 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Jeevan Scientific Technology's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jeevan Scientific Technology Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jeevan Scientific Technology's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Jeevan Scientific Technology's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jeevan Scientific Technology (BOM:538837) has a Pretax Margin % of 12.05% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Jeevan Scientific Technology and its competitors. This is 365% above median its historical median of 2.59. According to the industry distribution chart, Jeevan Scientific Technology ranks #243 out of 942 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Jeevan Scientific Technology's Pretax Margin % too high?
Jeevan Scientific Technology's current Pretax Margin % of 12.05% is 365% above median its 10-year median of 2.59. Based on the distribution chart, Jeevan Scientific Technology ranks #243 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jeevan Scientific Technology has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jeevan Scientific Technology's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jeevan Scientific Technology ranks #243 out of 942 companies for Pretax Margin %. This puts Jeevan Scientific Technology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Jeevan Scientific Technology and its competitors. Jeevan Scientific Technology's current Pretax Margin % is 12.05%, which is 365% above median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeevan Scientific Technology stock overvalued right now?
Based on GuruFocus' analysis, Jeevan Scientific Technology (BOM:538837) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹61.75, compared to a current price of ₹72.77 — trading 17.8% above its estimated fair value. The current Pretax Margin % is 12.05%, which is 365% above median its 10-year median of 2.59. Jeevan Scientific Technology's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Jeevan Scientific Technology (BOM:538837), the current Pretax Margin % is 12.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jeevan Scientific Technology (BOM:538837) Overvalued in 2026?
Based on GuruFocus' analysis, Jeevan Scientific Technology stock appears to be overvalued.
The current stock price of ₹72.77 is trading 17.8% above its estimated GF Value™ of ₹61.75.
GuruFocus considers Jeevan Scientific Technology to be Modestly Overvalued.
Key valuation signals for BOM:538837:
Pretax Margin %: 12.05% (365% above median its 10-year median of 2.59)
GF Value™: ₹61.75 vs. price of ₹72.77 (17.8% above fair value)
No single metric tells the full story. See the BOM:538837 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jeevan Scientific Technology Ltd is an India-based company engaged in providing clinical research and data management services. Jeevan Scientific is an independent clinical contract research organization, offering reliable, cost-effective, and technology-driven clinical research solutions to various clients across the globe. Its services offer high-value testing services, including bioanalytical services for small and large molecules, ranging across generics, biosimilars, and other new drugs. It operates in a single segment, namely clinical research services.
65GF Score
Get the complete analysis for BOM:538837
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538837 has been successfully added to your 
